Betaine as a determinant of postmethionine load total plasma homocysteine before and after B-Vitamin supplementation by Holm, Pål Ivar et al.
Betaine as a Determinant of Postmethionine Load Total
Plasma Homocysteine Before and After
B-Vitamin Supplementation
Pål I. Holm, Øyvind Bleie, Per M. Ueland, Ernst A. Lien, Helga Refsum,
Jan E. Nordrehaug, Ottar Nygård
Objective—Betaine is a substrate in the betaine–homocysteine methyltransferase reaction, converting homocysteine to
methionine. There are only sparse data on plasma betaine as a determinant of the plasma total homocysteine (tHcy)
concentration.
Methods and Results—Ninety patients undergoing coronary angiography were randomized into 4 groups administered
oral: (1) folic acid (0.8 mg), vitamin B12 (0.4 mg), and vitamin B6 (40 mg); (2) folic acid and vitamin B12; (3) vitamin
B6 alone; or (4) placebo. Nonfasting blood samples were collected at baseline and 3, 14, and 28 days and 3, 6, and 12
months after treatment start. A 4-hour methionine-loading test (0.1 g/kg) was performed at baseline and after 3 months.
At baseline, median (interquartile range) plasma betaine was 36.9 mol/L (range: 30.3 to 46.8) and was increased by
15% after methionine loading. The postmethionine load (PML) increase in tHcy was inversely related to plasma betaine
(0.29, P0.02) and even more strongly to PML betaine (0.47, P0.001). After 3 months of intervention, the
relation between the PML increase in tHcy and PML betaine was weakened (0.33, P0.007).
Conclusions—Plasma betaine is a strong determinant of the PML increase in tHcy in subjects not supplemented with
B-vitamins. (Arterioscler Thromb Vasc Biol. 2004;24:301-307.)
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Homocysteine is an established risk factor for occlusivevascular disease.1 High plasma concentration is also
associated with impaired cognitive function, Alzheimer dis-
ease, adverse pregnancy outcomes, and congenital malforma-
tions, particularly neural tube defects.2
The plasma concentration of total homocysteine (tHcy) is
determined by a variety of physiological, lifestyle, and
genetic factors and disease states.3 Among these, renal
function, folate, and cobalamin status are particularly influ-
ential.4 The vitamin effects are explained by the functions of
5-methyltetrahydrofolate as substrate and cobalamin as co-
factor in the ubiquitous methionine synthase reaction, which
catalyzes the remethylation of homocysteine to methionine.5
Vitamin B6, however, has no6,7 or a moderate8,9 effect on
plasma tHcy.
Methionine loading, which involves measurement of tHcy
after a standard oral methionine dose, was originally designed
to reveal defects in the vitamin B6-dependent transsulfuration
pathway.10 Plasma postmethionine load (PML) tHcy has
since been associated with cardiovascular risk independent of
basal tHcy.11 Folate, as well as vitamin B6 status,9,11 are
significant predictors of PML tHcy. These vitamin effects in
humans are at variance with the idea, based on enzymological
data,5 animal,12 and human studies,6 that PML tHcy is
determined by the activity of vitamin B6-dependent enzyme,
cystathionine -synthase, whereas the folate-dependent ho-
mocysteine remethylation regulates basal tHcy.
Betaine (trimethylglycine) is obtained in small amounts
through the diet or is generated in liver and kidney from
choline through the sequential action of choline oxidase (EC
1.1.3.17) and betaine-aldehyde dehydrogenase (EC
1.2.1.8).5,13 Betaine serves as methyl donor of the zinc
metalloenzyme, betaine-homocysteine methyltransferase
(BHMT; EC 2.1.1.5). This enzyme is mainly confined to the
liver and kidney and catalyzes an alternative route of homo-
cysteine remethylation to methionine5 (Figure 1). The role of
betaine as a methyl donor explains the observations that
betaine supplementation reduces tHcy in homocystinurics14
and in healthy individuals.15–18 Betaine also attenuates the
tHcy increase after methionine loading in healthy subjects16,18
and in cardiovascular19 and renal patients.20 However, except
for a recent Canadian study reporting on an inverse relation
between fasting tHcy and betaine in cardiovascular patients,21
no study has addressed the question of the role of endogenous
betaine as a determinant of basal and PML tHcy.
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Using a newly developed liquid chromatography–tandem
mass spectrometry method,22 we investigated the association
between plasma betaine and tHcy before and after methionine
loading in 90 subjects. The subjects were enrolled in the
Western Norway B-Vitamin Intervention Trial (WENBIT)
and followed-up for 1 year of B-vitamin intervention as
implemented in this trial.
Methods
Subjects
We investigated 90 consecutive patients enrolled in the WENBIT, an
ongoing study on the effects of tHcy-lowering therapy on mortality
and cardiovascular events in 3000 patients. Eligible subjects were
adult patients (older than 18 years) undergoing coronary angiography
for suspected coronary artery disease or aortic valvular stenosis.
Exclusion criteria were malignant disease, alcohol abuse, mental
illness, patient unwillingness to participate in long-term follow-up,
and participation in other studies. The subjects were recruited at
Haukeland University Hospital from April 1999 to September 1999.
Informed consent was obtained from all patients. The study protocol
was approved by the regional ethics committee and Norwegian
Medicines Agency.
Protocol
Recruited patients were randomized into 4 groups in a 22 factorial
block design. Group FB (n22) was administered daily folic acid
(0.8 mg), vitamin B12 (cyanocobalamin, 0.4 mg), and vitamin B6
(pyridoxine, 40 mg). Group F (n23) was administered folic acid
and vitamin B12. Group B (n21) was administered vitamin B6.
Group P (n24) was administered placebo. For the first 2 weeks, the
groups (FB and F) receiving folic acid were administered an
additional loading dose of folic acid (5 mg/d). Packages of trial
tablets were prepared and given serial number in random order in
blocks of 20 by Alpharma A/S (Copenhagen, Denmark). Compliance
monitoring was accomplished by tablet counting and by determina-
tion of vitamin B concentrations in plasma.
The subjects underwent a full routine medical examination at
baseline before coronary angiography. Coronary angiography was
performed 3 days after starting vitamin therapy.
Blood Collection and Biochemical Analyses
Nonfasting (basal) blood samples were collected at baseline, after 3
days, at 2 and 4 weeks, and at 3, 6, and 12 months of B-vitamin
intervention. A methionine loading test (0.1 g/kg body weight) was
performed at baseline and after 3 months. PML blood samples were
drawn at 4 hours after loading. EDTA blood samples were immedi-
ately placed on ice, centrifuged within 30 minutes, and EDTA
plasma stored at 80°C until analysis.
Routine blood analyses, including serum creatinine, were analyzed
at the Central Laboratory of Haukeland University Hospital on
Technicon Chem 1 (Bayer, Leverkusen, Germany). The tHcy,23
betaine, choline, di-MethylGlyoxime (DMG),22 cobalamin24 plasma
folate,25 and pyridoxal phosphate26 were analysed by published
methods.
Statistics
Because of skewed distribution of values for tHcy and some
metabolites, data are presented as median values with interquartile
ranges. Associations between variables were evaluated by Spearman
rank correlation and multiple linear regression analyses. Variables
considered likely to influence the outcome parameters were included
in the multivariate models. Mann-Whitney U test or Kruskal-Wallis
test was used for between-group comparisons of continuous vari-
ables, and Wilcoxon signed rank test was performed for comparison
within groups at baseline and after 3 months. Data were analyzed
using SPSS 11.0 (SPSS Inc.).
Results
Subject Characteristics and Blood Indices
at Baseline
A total of 90 patients were included. Their median age was 62
years (range 38 to 80); 77% were males. Blood indices at
baseline for the whole study group are given in Table 1.
Median betaine was 36.9 mol/L and median PML betaine
was 44.5 mol/L. One patient (in group P) had plasma
cobalamin (117 pmol/L) below the lower reference limit (200
pmol/L), along with elevated MMA (0.77 mol/L), and was
considered cobalamin-deficient. Plasma folate was below the
lower reference limit (4.5 nmol/L) in 10 patients.
Table 1 also shows the expected marked increase in tHcy
and also a moderate increase in median betaine (15%;
P0.001), choline (7%; P0.001), and DMG (18%;
P0.001) after methionine loading.
The concentrations of basal and PLM betaine in particular,
but also of choline and creatinine, were markedly higher in
males than in females (Table 1). No parameters differed
significantly according to treatment group, except basal tHcy
(18% difference; P0.04) and basal choline (15%; P0.01)
and PML choline (21%; P0.04) (data not shown). Details
on plasma pyridoxal phosphate26 and cobalamin27 in this
population have been given in separate publications.
Figure 1. Betaine metabolism, homocysteine remethylation, and
transsulfuration. Ado indicates adenosine; AdoHcy,
S-adenosylhomocysteine; AdoMet, S-adenosylmethionine; BAD,
betaine aldehyde dehydrogenase; Bet, betaine; BHMT, betaine-
homocysteine methyltransferase; CBS, cystathionine
-synthase; CL, cystathionine lyase; CH3THF, methyltetrahydro-
folate; CO, choline oxidase; DMG, dimethylglycine; Cys, cys-
teine; Cysta, cystathionine; Hcy, homocysteine; MAT, methio-
nine adenosyltransferase; Met, methionine; MT,
methyltransferase; MTR, methionine synthase; SAHH,
S-adenosylhomocysteine hydrolase; THF, tetrahydrofolate.
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Simple Correlations at Baseline
Simple correlations at baseline are shown in Table 2. Baseline
tHcy was positively related to age, creatinine, and basal
DMG, and were inversely related to plasma folate and
cobalamin.
The increase in tHcy after methionine loading (PML
tHcy) was not related to the levels of B-vitamins. The PML
tHcy showed a strong inverse association with PML betaine
(r0.37, P0.001) and a moderate association with basal
betaine (r0.23, P0.03), as also depicted in Figure 2.
The concentrations of betaine, choline, and DMG, mea-
sured before and after loading (PML), were significantly and
positively correlated (Table 2; data for choline and DMG not
shown).
Determinants of Betaine, Choline,
and Dimethylglycine
We assessed age, gender, creatinine, and the B-vitamins as
predictors of basal betaine, choline, and DMG at baseline by
multiple linear regression (Table 3). Betaine showed a strong
relation to sex, whereas choline in particular, but also DMG,
was positively related to creatinine. The metabolites were not
significantly related to any B vitamin, ie, folate, cobalamin,
or vitamin B6 (Table 3). Betaine, choline, and DMG mea-
sured after methionine loading showed similar relations to
gender, age, creatinine, and the B-vitamins as observed for
the basal concentrations (data not shown).
Betaine as a Determinant of PML tHcy
The PML tHcy was inversely associated with basal betaine
(model I), PML betaine (model II) (Table 3), and the PML
increase in betaine (0.27, P0.02) by multiple linear
regression. PML betaine was a stronger predictor than basal
betaine of PML tHcy. The regression models also included
age, sex, creatinine, and the B-vitamins, and these factors
were not significantly related to PML tHcy (Table 3).
Additional adjustment for basal or PML choline and basal or
PML DMG in the respective models had no effect (data not
shown).
Betaine, Choline, and DMG According to Duration
and Type of Intervention
Figure 3 depicts plasma concentrations for choline, betaine,
and DMG measured at intervals from baseline to 12 months.
PML concentrations at baseline and after 3 months are
included. The levels for betaine in particular, but also for
choline and DMG, were higher in men than in women
TABLE 1. Subject Characteristics and Blood Indices at Baseline According to Gender*
Total n90 Men n69 Women n21 P Value†
tHcy, mol/L 11.0 (9.3–12.9) 11.4 (9.8–13.0) 9.6 (7.7–12.9) 0.09
PML tHcy, mol/L 31.3 (27.0–37.6) 30.6 (27.1–36.0) 32.1 (24.3–39.0) 0.9
Betaine, mol/L 36.9 (30.3–46.8) 39.2 (33.2–48.0) 27.9 (22.8–33.0) 0.001
PML betaine, mol/L 44.5 (34.1–53.9) 47.2 (40.1–58.3) 29.3 (27.0–38.8) 0.001
Choline, mol/L 9.0 (7.7–10.7) 9.4 (7.9–11.0) 8.0 (7.3–8.9) 0.008
PML choline, mol/L 10.3 (8.3–11.4) 10.4 (8.4–12.0) 9.6 (7.0–11.0) 0.02
DMG, mol/L 3.64 (3.17–4.58) 3.67 (3.27–4.63) 3.32 (2.79–4.10) 0.1
PML DMG, mol/L 4.54 (3.58–5.44) 4.58 (3.72–5.42) 4.17 (3.42–6.11) 0.4
Age, y 62 (54–68) 62 (55–68) 62 (53–70) 1.0
Creatinine, mol/L 94 (87–101) 96 (89–103) 80 (73–93) 0.001
Folate, nmol/L 8.2 (6.1–11.1) 7.8 (6.1–10.9) 8.8 (6.6–12.2) 0.4
Cobalamin, pmol/L 369 (311–481) 373 (319–437) 355 (297–425) 0.6
Vitamin B6‡, nmol/L 23.0 (17.7–37.1) 22.9 (15.7–37.0) 23.0 (18.3–39.7) 0.5
*Data are given as medians with interquartile ranges (25th–75th percentiles) in parentheses.
†Mann-Whitney U test.
‡Pyridoxal phosphate.
tHcy indicates total homocysteine; PML, postmethionine load; DMG, dimethylglycine.
TABLE 2. Spearman Correlations at Baseline
Age Creatinine PML tHcy Betaine PML betaine Choline DMG Folate Cobalamin Vitamin B6
tHcy 0.50† 0.44† 0.40† 0.07 0.07 0.18 0.32* 0.21* 0.21* 0.08
PML tHcy 0.14 0.08 0.23* 0.37† 0.01 0.03 0.06 0.13 0.02
Betaine 0.13 0.07 0.79† 0.49† 0.42† 0.06 0.02 0.05
PML betaine 0.15 0.18 0.34* 0.33* 0.08 0.11 0.00
Choline 0.17 0.28* 0.50† 0.05 0.12 0.19
DMG 0.28* 0.15 0.14 0.1 0.09
*P0.05.
†P0.001.
tHcy indicates total homocysteine; PML, postmethionine load increase; DMG, dimethylglycine.
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throughout the intervention period and showed a transient
increase after methionine loading (Figure 3).
We compared the basal and PML concentrations of be-
taine, choline, and DMG at 3 months according to the
treatment groups FB, F, B, and P. The metabolite concentra-
tions, except PML choline (P0.03), were not significantly
different between the groups (P0.4) (data not shown).
B-Vitamin Supplementation and the
Betaine–PML tHcy Relationship
After 3 months of intervention, plasma cobalamin and plasma
folate were higher than 277 pmol/L and 25 nmol/L, respec-
tively, in all patients in groups FB and F, and pyridoxal
phosphate was higher than 142 nmol/L in groups FB and B.
No significant changes in median levels of these vitamins
occurred in the nonsupplemented groups.
PML tHcy (mol/L; median [interquartile range]) de-
creased in the groups FB (from 19.4 [15.5 to 22.7] to 14.7
[11.6 to 17.2], P0.004), F (from 19.7 [16.6 to 24.6] to 15.8
[12.9 to 18.9], P0.002), and B (from 19.3 [15.3 to 23.6] to
16.3 [13.5 to 17.9], P0.005) given B-vitamins. PML tHcy
did not change in the placebo group P (from 20.9 [17.0 to
30.0] to 21.8 [16.3 to 30.2], P0.5).
After 3 months of intervention, the inverse association
between PML tHcy and PML betaine in the subjects
receiving B-vitamins was essentially abolished but was still
present in the subgroup (P) receiving placebo, as depicted in
Figure 2. Multiple linear regression analyses of the associa-
tion between PML tHcy and PML betaine in the separate
intervention groups demonstrated that the association was
absent in the groups FB and F administered folic acid
(P0.6), showed a trend in the group B administered vitamin
B6 (P0.09), and was still strong and significant in the group
P administered no B-vitamins (0.66, P0.02). All these
models were adjusted for age, sex, creatinine, cobalamin,
folate, and vitamin B6.
Predictors of PML tHcy at 3 months in the whole study
group were assessed by multiple regression (Table I, avail-
able online at http://atvb.ahajournals.org). The model con-
tained the B-vitamins, in addition to creatinine, age, and sex.
Figure 2. The relation between plasma betaine and the PML
increase in plasma tHcy at baseline and after 3 months of
B-vitamin supplementation. The upper panels show the relations
between betaine (basal and PML) and PML increase in plasma
tHcy before intervention. The lower left panel shows PML
betaine versus PML increase in tHcy in 22 subjects (group P)
administered placebo and the lower right panel shows this rela-
tionship in the remaining 68 subjects (groups FB, F, and B)
treated with B-vitamins. The curves were obtained by quadratic
regression, and the shaded areas represent the 95% confidence
interval of mean regression line.
TABLE 3. Determinants at Baseline of Basal Betaine, Choline,
Dimethylglycine, and the increase in tHcy After Methionine
Loading by Multiple Linear Regression*
Dependent Variable Independent Variables  P





Vitamin B6 0.005 0.9





Vitamin B6 0.08 0.5





Vitamin B6 0.10 0.4





Vitamin B6 0.08 0.5
Basal betaine 0.29 0.02





Vitamin B6 0.02 0.9
PML betaine 0.47 0.001
*All variables are included in each of the models.
DMG indicates dimethylglycine; tHcy, total homocysteine.
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PML betaine was strongly associated with PML tHcy, but
the association was weaker (0.33, P0.007) than before
treatment (0.47, P0.001; Table 3). Plasma folate and,
to a lesser extent, vitamin B6 were also significant predictors.
Substitution of B-vitamin concentration with treatment
category in the regression model essentially did not change
the association between PML tHcy and PML betaine (data
not shown).
Discussion
We present data on the relation between betaine and plasma
tHcy in 90 patients with cardiovascular disease before and
during long-term intervention with folate, cobalamin, and
vitamin B6, as implemented in the WENBIT. We demon-
strate, for the first time to our knowledge, that the increase in
tHcy after methionine loading (PML tHcy) was determined
by PML betaine. Basal betaine was a weaker predictor. In 68
subjects supplemented with B-vitamins for 3 months, PML
tHcy was reduced, and its inverse relation to betaine was
weakened, particularly in the subgroups administered folic
acid.
Study Design
The strength of the study is its longitudinal, prospective
design, which allows comparison of betaine effects before
and after B-vitamin intervention in the same individuals. It
was clearly shown that in the combined group treated with
B-vitamins, the betaine-PML-tHcy association was essen-
tially abolished, but the small sample size provided limited
statistical power to delineate the effects of individual
B-vitamins.
We measured PML tHcy 4 hours after methionine inges-
tion. This short interval was chosen for logistic reasons. A
recent study demonstrated that at this time point, PML tHcy
has higher within-subject and between-subject coefficients of
variation (CV) than the PML tHcy measured at 6 or 8 hours
after methionine intake, possibly because of variable methi-
onine absorption a short time after loading.10 Furthermore, we
observed that betaine showed a stronger association with
PML tHcy than with PML tHcy. However, analytical CV
increases when PML tHcy is adjusted for basal tHcy to obtain
PML tHcy, because the variance has the property of being
additive.10 Thus, increased biological and analytical varia-
tions may actually lead to underestimation of the “true”
association between betaine status and PML tHcy.
Concentrations of Betaine, Choline,
and Dimethylglycine
The median plasma concentration of betaine reported here
(37 mol/L; Table 1) is similar to the concentration
previously reported by us in healthy blood donors22 and by
others.21,28 We observed a strong relation between betaine
and gender, with higher levels in males than in females (Table
1, Figure 3), which has also been reported by others.29 The
presence of consensus sites for steroid hormones, including
estrogen and androgen binding sites, in the human betaine
homocysteine methyltransferase gene30 may represent a mo-
lecular basis of sex steroid effects on plasma betaine.
We observed a median concentration of plasma choline
(9 mol/L) that is equal to the concentration (10 mol/L)
previously measured in healthy subjects22,31,32 The median
plasma DMG (3.6 mol/L) is somewhat higher than the
DMG levels (2 to 3 mol/L) previously reported by us and
others.22,28,33 Slightly elevated plasma DMG may be related
to the possibility that the cardiovascular patients have mod-
erately impaired renal function, which is known to affect the
DMG concentration.33 Conceivably, methodological differ-
ence may also account for different metabolite (DMG) levels
between various study populations.
Human Studies on Betaine and tHcy
The strong inverse association between PML tHcy and
plasma betaine, particularly PML betaine, in subjects not
receiving B-vitamin supplementation is the most important
result of the present study. The data are in agreement with
consistent observations that betaine supplementation reduces
PML tHcy and also fasting tHcy in healthy subjects16,18 and
tHcy in renal patients20 and in homocystinurics.34–36 How-
ever, our data (Table 2) do not confirm a recent observation
of a significant inverse relation between (basal) plasma
betaine and tHcy in 122 Canadian cardiovascular patients.21
Figure 3. Plasma concentration of choline, betaine, and dimeth-
ylglycine during B-vitamin supplementation and after methionine
loading. The metabolite concentrations are given separately for
men (filled circles) and women (open circles) according to time
after start of intervention. Arrows indicate methionine loading,
which was performed on day 0 and on day 84, and the values
obtained 4 hours after loading are included in the graph. Data
are given as medians and the shaded areas indicate the 25 to
75 percentiles.
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The apparent discrepancy may be related to different size,
B-vitamin status, or renal function of the two study popula-
tions. We are currently addressing the possible relation
between betaine and fasting tHcy in large population-based
studies.
Mechanisms and Role of Betaine in
Homocysteine Remethylation
Methionine loading caused a 3-fold increase in tHcy, a 15%
increase in plasma betaine and DMG, and also a significant
increase in choline (Table 1, Figure 3). The choline response
may reflect enhanced supply of choline for the synthesis of
betaine or a choline-sparing effect from superfluous methio-
nine. The elevation of plasma betaine and DMG levels,
however, indicates an increased flux through the BHMT
pathway, which is in accordance with the observation that
PML tHcy is strongly and inversely related to PML betaine
and also to PML increase in betaine. Thus, increased meta-
bolic flux through the choline-betaine-DMG pathway may
occur in response to high levels of homocysteine and/or
methionine.
After treatment with combinations of folic acid, vitamin
B12, and vitamin B6 for 3 months, the relation between PML
betaine and PML tHcy was weakened in the whole study
group and was abolished in the subgroups administered folic
acid. This indicates that enhancement of folate-dependent
remethylation catalyzed by methionine synthase downregu-
lates the BHMT reactions and suggests a cross-talk between
these two pathways.
The significance of betaine in homocysteine homeostasis is
not clear, but the view prevails that the BHMT mainly
functions to conserve homocysteine under conditions of
methionine deficiency.5 This assumption is based on animal
experiments demonstrating a dramatic induction of BHMT
during methionine deficiency in combination with excess
dietary choline.5,30,37–39
Our observation of an inverse relation between betaine and
PML tHcy indicates an additional function of the BHMT
pathway, ie, reduction of the homocysteine increase after
methionine intake. This idea is difficult to reconcile with the
fact that BHMT is inhibited by S-adenosylmethionine5 but
gains some support from experiments in rats, demonstrating a
moderate net increase in BHMT activity during methionine
excess.5 Suppression of high homocysteine under conditions
of excess methionine is thus obtained together with salvage of
homocysteine carbon backbone. This metabolic effect con-
trasts to the result of the vitamin B6-dependent cystathionine-
-synthase reaction, which irreversibly directs superfluous
homocysteine into the transsulfuration pathway.
Implications and Conclusion
The data presented here indicate that betaine through the
BHMT reaction buffers and tends to reduce homocysteine
during methionine excess. This reaction, which conserves the
homocysteine carbon backbone, may be beneficial under
conditions of limiting supply of folate required for enhance-
ment of the methionine synthase reaction. These findings
emphasize the complementary relationship between betaine
and folate metabolism and motivate population-based studies
on betaine status in pathologies related to folate deficiency
and homocysteine status.2 Furthermore, because PML tHcy
confers increased risk for occlusive vascular disease indepen-
dent of fasting tHcy,11 betaine and related metabolites should
be included in future studies of homocysteine and cardiovas-
cular risk. Because basal betaine showed a significant relation
to PML tHcy as well, the role of betaine could be investi-
gated in epidemiological studies based on biobanks, where
PML samples may not be available.
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